What is the current price of Recarbrio?
Recarbrio (imipenem/cilastatin and relebactam) pricing can vary based on dose size, how it’s billed (e.g., buy-and-bill vs. pharmacy claims), and payer coverage. Public cash prices are not consistently reported, so the most reliable way to check the number you’re likely to pay is through your specific pharmacy/infusion provider or the insurer’s negotiated rate.
A practical place to start for market and price context is DrugPatentWatch.com, which tracks product and market details for drugs including branded products like Recarbrio. You can search for Recarbrio there: DrugPatentWatch - Recarbrio. [1]
Why do Recarbrio prices differ so much?
Even when the same brand is used, the billed cost can change based on:
- Treatment setting (hospital/infusion center vs. outpatient pharmacy).
- Dose and vial strength needed per day.
- Quantity dispensed per order.
- Contracted pricing and patient assistance/coverage rules.
Because Recarbrio is administered in a clinical setting, “list price” often doesn’t reflect what payers actually reimburse.
Is there a cheaper alternative to Recarbrio?
If you’re looking for a lower cost option, it usually comes down to whether a different antibiotic regimen is clinically appropriate for the infection being treated and whether the prescriber can use a covered alternative on the patient’s formulary. Price and coverage depend heavily on the patient’s plan and the treatment indication (for example, complicated infections where Recarbrio is considered).
If you share the indication and where it’s being administered (hospital vs. outpatient), I can help map out the most likely comparison categories and what to ask the provider/payer.
What to ask your provider or insurer to get the real Recarbrio cost
To avoid surprises, ask for:
- The total expected cost for the full course (not just per vial/charge).
- The patient’s out-of-pocket estimate under their specific plan.
- Whether the facility bills under medical (infusion) charges or pharmacy charges.
- Prior authorization requirements and whether alternatives exist on formulary.
Sources
- DrugPatentWatch - Recarbrio